Genesis was a member of the Broad Cardiovascular Disease Research group as a Research Associate from 2016-2018.
He received his B.S. in Bioengineering from the California Institute of Technology in 2015. During his time in the lab, he was supported by the Broad Bayer collaboration characterizing a novel cardiovascular drug target. His work involved the use of CRISPR in cardiomyocytes as well as the study of enzymatic function and protein design in collaboration with the Broad Center for the Development of Therapeutics (CDoT).
Genesis is currently a Senior Research Associate at Beam Therapeutics focused on developing CRISPR based treatment strategies.